Research location
Kennewick
Washington, United States
Advertisement
Research activity in Kennewick
Washington, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 193 trials and 218 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Kennewick
193 linked trials · page 2 of 4Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT03087708 · 2018-03-23 · 1 site observation
TERMINATED
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03334487 · 2018-03-15 · 1 site observation
WITHDRAWN
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesNCT03365791 · 2018-01-24 · 1 site observation
COMPLETED
Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCNCT03326674 · 2017-12-21 · 1 site observation
TERMINATED
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 2 site observations
COMPLETED
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer ParticipantsNCT03308942 · 2017-09-29 · 1 site observation
COMPLETED
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke CigarettesNCT02856581 · 2017-09-29 · 1 site observation
TERMINATED
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic CancerNCT03180294 · 2017-05-31 · 1 site observation
COMPLETED
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872 · 2017-03-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)NCT03036488 · 2017-03-07 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 2 site observations
COMPLETED
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30 · 2 site observations
ACTIVE_NOT_RECRUITING
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 2 site observations
TERMINATED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 2 site observations
ACTIVE_NOT_RECRUITING
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesNCT02595905 · 2016-09-15 · 1 site observation
COMPLETED
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerNCT02642042 · 2016-07-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)NCT02753595 · 2016-07-13 · 1 site observation
TERMINATED
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)NCT02817633 · 2016-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid ArthritisNCT02728934 · 2016-02-25 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 2 site observations
ACTIVE_NOT_RECRUITING
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyNCT02445391 · 2015-10-20 · 2 site observations
ACTIVE_NOT_RECRUITING
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerNCT02481830 · 2015-09-14 · 1 site observation
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 2 site observations
ACTIVE_NOT_RECRUITING
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)NCT02477826 · 2015-08-05 · 1 site observation
COMPLETED
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerNCT02441946 · 2015-08-01 · 1 site observation
COMPLETED
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNCT02488967 · 2015-07-26 · 2 site observations
ACTIVE_NOT_RECRUITING
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 2 site observations
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes MellitusNCT02106364 · 2015-02-01 · 1 site observation
WITHDRAWN
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT02278120 · 2014-11-20 · 1 site observation
COMPLETED
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01 · 2 site observations
COMPLETED
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchNCT02231164 · 2014-10-14 · 1 site observation
TERMINATED
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerNCT02152631 · 2014-10-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · 2014-10-01 · 2 site observations
COMPLETED
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26 · 2 site observations
ACTIVE_NOT_RECRUITING
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · 2014-09-01 · 2 site observations
COMPLETED
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)NCT02187783 · 2014-08-25 · 1 site observation
COMPLETED
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · 2014-07-31 · 2 site observations
COMPLETED
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerNCT02107703 · 2014-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08 · 2 site observations
COMPLETED
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their ChildrenNCT02129049 · 2014-04-01 · 2 site observations
COMPLETED
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticNCT02115282 · 2014-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryNCT01953588 · 2014-02-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With ChemotherapyNCT01901094 · 2014-02-24 · 3 site observations
ACTIVE_NOT_RECRUITING
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18 · 1 site observation
COMPLETED
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung CancerNCT02027428 · 2014-02-11 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.